Excedrin and Bufferin products are part of the voluntary recall.
Novartis says "stray" pills "from other Novartis products" put in the wrong package.
An internal probe also found evidence of "broken gelcaps (and) chipped tablets".
The recall and processing upgrades will cost $120 million, Novartis estimates.
